An Extension Trial of Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, for Patients With Advanced Cancer.

Trial Profile

An Extension Trial of Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, for Patients With Advanced Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Ridaforolimus (Primary) ; Ridaforolimus (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 11 Oct 2017 Planned End Date changed from 21 Sep 2017 to 16 Jan 2018.
    • 11 Oct 2017 Planned primary completion date changed from 21 Sep 2017 to 16 Jan 2018.
    • 03 Apr 2017 Planned End Date changed from 1 Mar 2017 to 21 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top